Long non-coding RNA SLC۱۶A۱-AS۱ and different human cancers: a novel therapeutic target and prognostic biomarker

سال انتشار: 1401
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 71

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

HUMS04_131

تاریخ نمایه سازی: 3 خرداد 1402

چکیده مقاله:

Introduction and Objective: Cancer is a complex disease associated with a variety of genetic mutations. Non-coding RNAs (ncRNAs) play important roles in the molecular biology of cancer mainly by regulating gene expression at multiple levels. Long non-coding RNAs (lncRNAs that are >۲۰۰ nt in length) have been demonstrated to have important roles in cellular processes including cell cycle progression, cell differentiation, growth, and differentiation. LncRNAs establish competing endogenous RNA (ceRNA) networks to regulate the expression of the protein-coding genes. The various functions of SLC۱۶A۱-AS۱ LncRNA in different cancers have been literally approved but the generalizability of many published papers on this issue is problematic, and such expositions are unsatisfactory because there isn’t a comprehensive review of this LncRNA. So, this review article has been conducted.Method: The Scopus ,PubMed and Google Scholar databases were used for collecting the data.Results: SLC۱۶A۱-AS۱ is a tumor-suppressive lncRNA in non-small cell lung cancer (NSCLC) and Breast cancer. Its down-regulation predicted poor overall survival in these patients. In addition, the up-regulation of SLC۱۶A۱-AS۱ repressed invasion, colony formation, and migration of these cancer cells. SLC۱۶A۱-AS۱ may play an oncogenic role in glioblastoma multiforme, bladder cancer, stomach adenocarcinoma and hepatocellular carcinoma (HCC) and its increased expression is an indicator of poor overall survival of these patients. SLC۱۶A۱-AS۱ was up-regulated in HCC and may play an oncogenic role by down-regulating miRNA-۱۴۱ through methylation.Conclusion: This review indicates that SLC۱۶A۱-AS۱ can be a novel therapeutic target and prognostic biomarker in different cancers.

کلیدواژه ها:

نویسندگان

Amirhossein Mohajeri Khorasani

Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Science, Bandar Abbas, Iran

Atefe Ebrahimi Tamandegani

Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Science, Bandar Abbas, Iran

Pegah Mousavi

Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran